Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C, its new therapeutic, aimed at treating upper respiratory infections, including Covid-19.
The trial findings suggest that SJP-002C had an ‘exceptional’ safety profile without any adverse events reported. Additionally, the therapy’s ‘efficacy’ was demonstrated with the improvement in minimising the symptoms, especially on the first and second days of treatment.
Sen-Jam Pharmaceutical chief clinical officer and co-founder Jackie Iversen said: "The strong safety profile and early symptom improvements are promising indicators of SJP-002C's potential to make a meaningful impact in Covid-19 care.
"We are energised by these results and remain committed to refining the efficacy of this therapeutic to serve a broader population."
According to the company, these outcomes signal the therapy’s potential in treating upper respiratory infections. However, further research is necessary to confirm its statistical and clinical significance.
More clinical data is being examined by the company currently to better understand the therapeutic's performance and it is considering additional studies to broaden SJP-002C's application to a wider range of patients and conditions.
Earlier in the week, Sen-Jam reported that its another lead asset, SJP-001, obtained ethics approval for a clinical trial in Australia. The trial will assess the therapy’s efficacy and safety in metabolic health and managing overindulgence symptoms.
This trial will be conducted by early-phase clinical research organisation, Nucleus Network, with support from full-service clinical Contract Research Organisation (CRO), Novotech.
Leveraging its ‘Pleiotropic Anti-Inflammatory Remedies’ (PAIR) technology, designed to address chronic inflammation and metabolic disorders, Sen-Jam focuses on precision remedies that align with the body's natural resilience.
In May 2022, the company commenced subject enrolment for the Phase II clinical trial of SJP-002C in Nepal.
